Microsoft’s data-center shortages to persist longer than expected - Bloomberg
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating and $65.00 price target on Structure Therapeutics (NASDAQ:GPCR), maintaining its positive outlook on the clinical-stage biopharmaceutical company. The target represents significant upside potential from the current price of $22.08, with analyst targets ranging from $37 to $120.
The firm highlighted a significant upcoming catalyst for Structure Therapeutics by year-end 2025 - Phase 2B obesity readouts from the ACCESS-1 and ACCESS-2 trials for its oral GLP-1 drug candidate aleniglipron.
Cantor Fitzgerald views Structure Therapeutics’ current valuation of $1.3 billion market cap (enterprise value of approximately $500 million) as "very attractive" heading into this catalyst period.
The firm noted that recent obesity data in the sector has created a favorable setup for Structure Therapeutics, with "risk/reward meaningfully skewed to the upside" as expectations for aleniglipron have moderated.
Looking further ahead, Cantor Fitzgerald pointed to multiple readouts in 2026 that could differentiate Structure Therapeutics’ pipeline, including data on oral amylin and longer duration results for higher doses of aleniglipron.
In other recent news, Structure Therapeutics has been the focus of several analyst updates. Guggenheim lowered its price target for the company to $90 while maintaining a Buy rating, citing that the company is on track with its Phase 2b ACCESS and ACCESS II studies for its oral small molecule GLP1RA aleniglipron, with results expected by the end of 2025. Similarly, JMP Securities adjusted its price target to $87, maintaining a Market Outperform rating, and anticipates a positive impact on Structure Therapeutics shares following Eli Lilly’s upcoming data presentation. Clear Street initiated coverage with a Buy rating and a $61 price target, highlighting the company’s potential in the oral drug market. Cantor Fitzgerald reiterated its Overweight rating and $65 price target, referencing recent trial data from Eli Lilly that could have implications for Structure Therapeutics’ developments. Additionally, H.C. Wainwright reiterated a Buy rating with a $75 price target, following promising data on oral GLP-1R agonists presented at a recent diabetes conference. These developments reflect ongoing interest and analysis in Structure Therapeutics’ progress in the pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.